Medtronic Plc (MDT)

$79.75

-0.2

(-0.25%)

Market is closed - opens 7 PM, 20 Jun 2024
star icon

Medtronic PLC is a global medical device company that provides innovative solutions to improve patient outcomes and reduce healthcare costs.

Insights on Medtronic Plc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 7.70B → 8.58B (in $), with an average increase of 3.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.32B → 654.0M (in $), with an average decrease of 50.5% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 40.5% return, outperforming this stock by 51.0%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 77.4% return, outperforming this stock by 112.7%

Performance

  • $79.17
    $80.30
    $79.75
    downward going graph

    0.73%

    Downside

    Day's Volatility :1.41%

    Upside

    0.68%

    downward going graph
  • $67.71
    $88.75
    $79.75
    downward going graph

    15.1%

    Downside

    52 Weeks Volatility :23.71%

    Upside

    10.14%

    downward going graph

Returns

PeriodMedtronic PlcSector (Health Care)S&P500
3 Months
-5.18%
0.1%
6.7%
6 Months
-2.83%
8.3%
15.1%
1 Year
-10.33%
10.4%
24.4%
3 Years
-36.47%
17.9%
31.7%

Highlights

Market Capitalization
106.3B
Book Value
$38.29
Dividend Share
2.76
Dividend Yield
3.46%
Earnings Per Share (EPS)
2.76
PE Ratio
29.36
PEG Ratio
1.52
Wall Street Target Price
93.25
Profit Margin
11.36%
Operating Margin TTM
21.68%
Return On Assets TTM
4.46%
Return On Equity TTM
7.26%
Revenue TTM
32.4B
Revenue Per Share TTM
24.38
Quarterly Revenue Growth YOY
0.5%
Gross Profit TTM
21.7B
EBITDA
9.1B
Diluted Eps TTM
2.76
Quarterly Earnings Growth YOY
-0.44
EPS Estimate Current Year
5.2
EPS Estimate Next Year
5.45
EPS Estimate Current Quarter
1.45
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    51%Buy
    43%Hold
    5%Sell
Based on 37 Wall street analysts offering stock ratings for Medtronic Plc(by analysts ranked 0 to 5 stars)
Based on 37 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
19
20
Hold
16
16
15
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 16.93%

Current $79.75
Target $93.25

Company Financials

FY19Y/Y Change
Revenue
30.6B
↑ 2.02%
Net Income
4.6B
↑ 49.19%
Net Profit Margin
15.16%
↑ 4.8%
FY20Y/Y Change
Revenue
28.9B
↓ 5.38%
Net Income
4.8B
↑ 3.41%
Net Profit Margin
16.56%
↑ 1.4%
FY21Y/Y Change
Revenue
30.1B
↑ 4.16%
Net Income
3.6B
↓ 24.7%
Net Profit Margin
11.97%
↓ 4.59%
FY22Y/Y Change
Revenue
31.7B
↑ 5.21%
Net Income
5.0B
↑ 39.74%
Net Profit Margin
15.9%
↑ 3.93%
FY23Y/Y Change
Revenue
31.2B
↓ 1.45%
Net Income
3.8B
↓ 25.42%
Net Profit Margin
12.03%
↓ 3.87%
FY24Y/Y Change
Revenue
32.4B
↑ 3.64%
Net Income
3.7B
↓ 2.16%
Net Profit Margin
11.36%
↓ 0.67%
Q1 FY23Q/Q Change
Revenue
7.7B
↑ 1.87%
Net Income
1.2B
↑ 186.18%
Net Profit Margin
15.81%
↑ 10.18%
Q2 FY23Q/Q Change
Revenue
8.5B
↑ 10.57%
Net Income
1.2B
↓ 3.52%
Net Profit Margin
13.8%
↓ 2.01%
Q3 FY23Q/Q Change
Revenue
7.7B
↓ 9.85%
Net Income
791.0M
↓ 32.91%
Net Profit Margin
10.27%
↓ 3.53%
Q4 FY23Q/Q Change
Revenue
8.0B
↑ 3.66%
Net Income
909.0M
↑ 14.92%
Net Profit Margin
11.39%
↑ 1.12%
Q1 FY24Q/Q Change
Revenue
8.1B
↑ 1.32%
Net Income
1.3B
↑ 45.43%
Net Profit Margin
16.34%
↑ 4.95%
Q2 FY24Q/Q Change
Revenue
8.6B
↑ 6.18%
Net Income
654.0M
↓ 50.53%
Net Profit Margin
7.61%
↓ 8.73%
FY19Y/Y Change
Total Assets
89.7B
↓ 1.86%
Total Liabilities
39.5B
↓ 2.68%
FY20Y/Y Change
Total Assets
90.7B
↑ 1.11%
Total Liabilities
39.8B
↑ 0.85%
FY21Y/Y Change
Total Assets
93.1B
↑ 2.64%
Total Liabilities
41.5B
↑ 4.18%
FY22Y/Y Change
Total Assets
91.0B
↓ 2.26%
Total Liabilities
38.3B
↓ 7.77%
FY23Y/Y Change
Total Assets
90.9B
↓ 0.04%
Total Liabilities
39.3B
↑ 2.68%
FY24Y/Y Change
Total Assets
90.0B
↓ 1.06%
Total Liabilities
39.6B
↑ 0.71%
Q1 FY23Q/Q Change
Total Assets
94.1B
↑ 0.96%
Total Liabilities
42.5B
↑ 3.23%
Q2 FY23Q/Q Change
Total Assets
90.9B
↓ 3.38%
Total Liabilities
39.3B
↓ 7.6%
Q3 FY23Q/Q Change
Total Assets
90.8B
↓ 0.19%
Total Liabilities
39.4B
↑ 0.32%
Q4 FY23Q/Q Change
Total Assets
90.1B
↓ 0.76%
Total Liabilities
38.4B
↓ 2.46%
Q1 FY24Q/Q Change
Total Assets
90.8B
↑ 0.83%
Total Liabilities
38.8B
↑ 1.04%
Q2 FY24Q/Q Change
Total Assets
90.0B
↓ 0.94%
Total Liabilities
39.6B
↑ 1.85%
FY19Y/Y Change
Operating Cash Flow
7.0B
↑ 49.59%
Investing Cash Flow
-774.0M
↓ 113.21%
Financing Cash Flow
-5.4B
↓ 54.57%
FY20Y/Y Change
Operating Cash Flow
7.2B
↑ 3.24%
Investing Cash Flow
-3.2B
↑ 313.82%
Financing Cash Flow
-4.2B
↓ 22.7%
FY21Y/Y Change
Operating Cash Flow
6.2B
↓ 13.74%
Investing Cash Flow
-2.9B
↓ 10.52%
Financing Cash Flow
-4.1B
↓ 1.48%
FY22Y/Y Change
Operating Cash Flow
7.3B
↑ 17.72%
Investing Cash Flow
-1.7B
↓ 42.11%
Financing Cash Flow
-5.3B
↑ 29.01%
FY23Y/Y Change
Operating Cash Flow
6.0B
↓ 17.79%
Investing Cash Flow
-3.5B
↑ 110.55%
Financing Cash Flow
-5.0B
↓ 7.05%
Q1 FY23Q/Q Change
Operating Cash Flow
1.6B
↑ 70.72%
Investing Cash Flow
-3.0B
↑ 163.35%
Financing Cash Flow
-2.1B
↓ 170.8%
Q2 FY23Q/Q Change
Operating Cash Flow
2.5B
↑ 56.29%
Investing Cash Flow
-475.0M
↓ 84.26%
Financing Cash Flow
-4.9B
↑ 129.15%
Q3 FY23Q/Q Change
Operating Cash Flow
875.0M
↓ 64.43%
Investing Cash Flow
-539.0M
↑ 13.47%
Financing Cash Flow
-501.0M
↓ 89.75%
Q4 FY23Q/Q Change
Operating Cash Flow
661.0M
↓ 24.46%
Investing Cash Flow
-424.0M
↓ 21.34%
Financing Cash Flow
-90.0M
↓ 82.04%

Technicals Summary

Sell

Neutral

Buy

Medtronic Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Medtronic Plc
Medtronic Plc
-5.63%
-2.83%
-10.33%
-36.47%
-19.24%
Stryker Corporation
Stryker Corporation
5.74%
19.42%
17.08%
34.24%
73.91%
Boston Scientific Corp.
Boston Scientific Corp.
1.26%
36.71%
41.21%
75.02%
83.17%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-1.4%
17.54%
-3.69%
-13.92%
39.04%
Abbott Laboratories
Abbott Laboratories
0.76%
-4.09%
-2.54%
-6.69%
23.31%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Medtronic Plc
Medtronic Plc
29.36
29.36
1.52
5.2
0.07
0.04
0.03
38.29
Stryker Corporation
Stryker Corporation
39.35
39.35
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
64.5
64.5
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.61
37.61
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
32.3
32.3
5.99
4.63
0.15
0.06
0.02
22.31
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Medtronic Plc
Medtronic Plc
Buy
$106.3B
-19.24%
29.36
11.36%
Stryker Corporation
Stryker Corporation
Buy
$131.3B
73.91%
39.35
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$112.9B
83.17%
64.5
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.6B
39.04%
37.61
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$180.4B
23.31%
32.3
13.96%

Institutional Holdings

  • Vanguard Group Inc

    9.63%
  • BlackRock Inc

    8.69%
  • State Street Corporation

    4.58%
  • JPMorgan Chase & Co

    2.41%
  • Capital Research Global Investors

    2.36%
  • Morgan Stanley - Brokerage Accounts

    2.06%

Corporate Announcements

  • Medtronic Plc Dividends March,2024

    In the quarter ending March,2024. Medtronic Plc has declared dividend of $0.69

    Read More

Company Information

Medtronic plc is an American medical device company. The companys operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015.

Organization
Medtronic Plc
Employees
95000
CEO
Mr. Geoffrey Straub Martha
Industry
Health Technology

FAQs